Third-party companies known as pharmacy benefit managers, which administer prescription drug benefits for health insurance plans, employers, and other organizations including governments, are driving up prescription drug costs, putting small pharmacies out of business, and interfering in the relationship between doctors and their patients, says Sen. Rochelle Nguyen, a Democrat from Las Vegas and the sponsor of Senate Bill 316, a measure that seeks to reform PBMs.

Annual lung cancer screening, or LCS, detects cancer at a higher rate and at earlier stages, findings suggest.

During Colorectal Cancer Awareness Month, CURE sat down for an interview with Dr. Shyam Thakkar to discuss a wide range of topics related to the disease, including its rising rates in younger adults, the potential role of artificial intelligence and disparities that currently persist among this patient population.

How oncologists approach end-of-life care for cancer remains the subject of much discussion and concern, with some experts fearing that patients are not being heard.

The death Sunday of former U.S. Rep. Mia Love, the first Black Republican woman elected to the U.S. House, has brought renewed attention to an aggressive form of brain cancer that killed her at age 49.

As a Native American and former president of the Seneca Nation of Indians, I am keenly aware of the disparities in cancer care we face in accessing screening and treatment, which results in worse survival rates compared with those of racial and ethnic populations.1

Whether insurance companies will be required to continue covering the full cost of preventive health services—a policy credited with saving more than 100,000 lives a year—is in the hands of the U.S. Supreme Court.

The routine is familiar for most people: When checking in for an appointment with a doctor or other health care provider, patients typically complete and sign a pile of paperwork, including a form that contains some version of the statement, "I agree to pay for all charges not covered by my insurance company."

Cancer death rates have dropped 34% between 1991 and 2022, which the ACS attributes to early detection, smoking reduction and improvements in treatment.

Lobectomy, a standard treatment for patients with stage 1 non-small cell lung cancer (NSCLC), is not advised for people with high risk of postsurgical complications or mortality.